Effect of continuing the use of renin–angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis

Table 4 Subgroup analysis by the baseline blood pressure

	No. of studies	Con event/total	Discon event/total	I² (%)	P value for heterogeneity	RR 95% CI	Overall effect Z/P value
Hospital mortality subgroup analysis by blood pressure
With comparable blood pressure	3	13/399	220/386	0	0.50	0.52 [0.27, 1.02]	1.9/0.06
Part of patients with hypotension in the discontinuing group	3	27/321	84/253	0	0.92	0.24 [0.16, 0.35]	7.07/< 0.00001
With unstated blood pressure	3	118/492	174/616	0	0.18	0.76 [0.52, 1.13]	1.35/0.18
30-day mortality subgroup analysis by blood pressure
With comparable blood pressure	4	34/525	30/536	0	0.74	1.15 [0.72, 1.84]	0.59/0.56
Part of patients with hypotension in the discontinuing group	1	7/78	13/39	NA	NA	0.27 [0.12, 0.62]	3.08/< 0.002
Rate of ICU admission subgroup analysis by blood pressure
With comparable blood pressure	4	44/249	50/233	42	0.16	0.76 [0.45, 1.28]	1.02/0.31
Part of patients with hypotension in the discontinuing group	2	30/242	59/210	0	0.55	0.43 [0.29, 0.64]	4.18/< 0.0001
With unstated blood pressure	2	28/436	44/499	68	0.08	0.71 [0.31, 1.51]	0.83/0.41
Rate of IMV subgroup analysis by blood pressure
With comparable blood pressure	5	53/574	62/567	0	0.71	0.81 [0.57, 1.14]	1.21/0.23
Part of patients with hypotension in the discontinuing group	1	6/79	14/43	NA	NA	0.23 [0.10, 0.56]	3.24/0.001
With unstated blood pressure	1	7/151	20/159	NA	NA	0.62 [0.46, 0.83]	3.20/0.001

Con continuation, Dis discontinuation, NA not applicable, ICU intensive care unit, IMV invasive mechanical ventilation, RR risk ratio, CI confidence interval

ISSN: 1471-2334